US Patent

US7687516 — Alcohol free formulation of argatroban

Method of Use · Assigned to Eagle Pharmaceuticals Inc · Expires 2027-09-26 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects an alcohol-free formulation of argatroban, including a 1 mg/ml injectable dosage form with argatroban, lactobionic acid, and methionine.

USPTO Abstract

An aqueous formulation of argatroban and of related compounds is disclosed along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo-saccharides. An especially preferred embodiment is a ready-to-administer 1 mg/ml injectable dosage form having argatroban, lactobionic acid, and methionine.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1164 — Argatroban

Patent Metadata

Patent number
US7687516
Jurisdiction
US
Classification
Method of Use
Expires
2027-09-26
Drug substance claim
No
Drug product claim
Yes
Assignee
Eagle Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.